Condition category
Nervous System Diseases
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
Multiple Sclerosis (MS) is an autoimmune inflammatory disease that causes damage to the myelin sheaths of the nerves in the central nervous system. MS is commonly diagnosed between the ages of 20-40 and is three times more likely to affect women than men. Most (80%) of MS patients report lower urinary tract symptoms (LUTS). The most common is urge incontinence (a sudden need to use the toilet followed immediately by urinating), but MS sufferers also report urinary tract infections(UTIs).UTIs have been associated with relapses and progression of MS. UTIs can made the neurological symptoms in MS worse whilst high-dose steroid treatment of acute neurological worsening may lead to diagnosis of an UTI that had not previously been identified. Half of the women with MS will have at least one episode of UTI requiring antibiotic therapy during their lifetime. Moreover, 25-35% of initial UTI episodes are followed by a recurrent infection within 3-6 months. The chances of someone developing a UTI is complex and depends on genetic, biologic, and behavioural factors. Among the recognised factors, the interaction between the bacteria and the epithelial cells lining the bladder wall is thought to be important. Damage to a layer lining the bladder (the glycosaminoglycan or GAG layer) may expose epithelial cells to urine, which, in turn, may lead to infection. Various approaches have been developed towards a reversal of the damage and a reconstruction of the GAG layer, including the use of heparin, oral pentosan polysulphate, and hyaluronic acid (HA). HA is a major mucopolysaccharide widely found in the connective, epithelial, and neural tissues. Chondroitin sulphate (CS) is also an important structural component for bladder mucosal integrity. Both HA and CS are known to work well in treating cystitis (bladder infection). This suggests that a similar therapeutic approach might be beneficial for treating recurrent UTI. We want to investigate the performance and tolerability of oral administration of combined HA andCS in reducing UTIs and improving the quality of life (QoL) in female patients with multiple sclerosis and a history of recurrent UTIs.

Who can participate?
Women (over 18) with MS that have had at least three UTIs

What does the study involve?
Participants first go to a screening visit to see whether they are eligible. This involves assessment of age, clinical history, symptoms and quality of life. Participants are then randomly allocated into one of two groups. Those in group 1 are given one combined HA and CS capsule twice a day, every day, for 2 weeks and then once a day, every day, for two months. Those in group 2 are given a placebo twice a day, every day, for 2 weeks and then once a day, every day, for two months. UTI assessments are made for all participants before they start the treatment and then after 4,8 and, finally, 12 months.

What are the possible benefits and risks of participating?
Not provided at time of registration.

Where is the study run from?
The Second University of Naples (SUN) Urology Clinic

When is the study starting and how long is it expected to run for?
May 2015 to May 2016

Who is funding the study?
IBSA (Institut Biochimique SA)

Who is the main contact?
Dr Marco De Sio

Trial website

Contact information



Primary contact

Dr Marco De Sio


Contact details

Piazza Miraglia

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Hyaluronic acid and chondroitin sulphate (Ialuril soft gel ® HA 20 mg, CS 200 mg, curcuma longa 200 mg, quercetina 200 mg) versus placebo in the prevention of urinary infections in female patients with multiple sclerosis: a single centre, randomized, placebo-controlled, double-blind trial


Study hypothesis

The aim of this study is to investigate the efficacy and tolerability of oral administration of combined HA and CS in reducing the rate of UTI and improving the quality of life (QoL) in female patients with multiple sclerosis and a history of recurrent UTIs.

Ethics approval

Not provided at time of registration

Study design

Placebo-controlled randomized trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet


Multiple Sclerosis


Eligible patients will receive 1 capsule twice a day of HA and CS (Ialuril soft gel ® HA 20 mg, CS 200 mg, Curcuma longa 200 mg, Quercetina 200 mg), or a placebo every day for two weeks and then once a day for two months.

Intervention type



Drug names

Primary outcome measure

Mean rate of UTI episodes per patient per year. A UTI episode was defined in the form of significant bacteriuria as >10000 CFU/ml of midstream urine with clinical symptoms.

Assessments measured at baseline and after 4,8 and 12 months.

Secondary outcome measures

1. Time to UTI recurrence (defined as the time relapsed between the first administration and the first recurring infection)
2. Variation in void frequency and volume
3. Impact of therapy on QoL
4. Rate of adverse events

Assessments measured at baseline and after 4,8 and 12 months.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Female
2. Age >18years
3. Diagnosis of MS according to the McDonald Revised criteria
4. Expanded Disability Status Scale less < 8
5. Documented history of recurrent cystitis defined as at least three episodes of uncomplicated infection documented by urine culture with the isolation of >10000 CFU/ml of an identified pathogen in the last year with clinical symptoms

Participant type


Age group




Target number of participants

Efficacy data were based both on previously reported data and our own experience in daily clinical practice at our institution. Using type I error and a power of 5% and 80%, respectively, and by proposing the hypothesis that HA would be able to induce a 70% decrease of UTI rate per patient per year, it was calculated that 30 subjects per group were necessary to detect this difference

Participant exclusion criteria

1. Age >80 years
2. UTIs in the previous year < 3
3. Concomitant UTI at the beginning of the study or ongoing prophylactic antibiotic treatment
4. Known neoplasia, urinary stone or abnormality of the urinary tract
5. Chronic kidney disease, diabetes mellitus, use of spermicides or intrauterine devices

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

The Second University of Naples (SUN) Urology Clinic (Seconda Università degli studi di Napoli Clinica Urologica)
Piazza Miraglia Napoli

Sponsor information


The Second University of Naples (Seconda Università degli studi di Napoli)

Sponsor details

Piazza Miraglia

Sponsor type




Funder type


Funder name

IBSA (Institut Biochimique SA)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Intention to publish date

Participant level data

Not expected to be available

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes